Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 13/20 | 0.51 |
| ▸ | SULT1A1 | P50225 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416207 | 0.85 | MAPT (0.69) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL5415895 | 0.83 | MAPT (0.55) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL27648807 | 0.79 | MAPT (0.67) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL4232232 | 0.77 | APP (0.61) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL13806301 | 0.76 | APP (0.62) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL13806292 | 0.75 | APP (0.55) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL5416199 | 0.74 | TP53 (0.77) | MAPTKDM4ENPC1RAB9AAPP | |
| SCHEMBL13806264 | 0.74 | APP (0.68) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL5756441 | 0.74 | MAPT (0.61) | MAPTKDM4ENPC1RAB9ANPSR1 | |
| SCHEMBL2802355 | 0.73 | RAB9A (0.71) | MAPTKDM4ENPC1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20070208066-A1 | ER-beta-selective ligands | BARLAAM BERNARD | 2007-09-06 | — | — | US | disclosed |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | BARLAAM BERNARD | 2006-05-25 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | MAPT 388/4885KDM4E 2759/4885NPC1 2588/4885 |
| US-20070208066-A1 | ER-beta-selective ligands | ESR2, ESRRG, ESRRA | MAPT 592/4885KDM4E 2761/4885NPC1 2976/4885 |
| US-20060111408-A1 | Therapeutic benzothiazole compounds | ESR1, ESR2, ESRRG | MAPT 221/4885KDM4E 1759/4885NPC1 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.